Cell Biosciences Buying Convergent Bioscience for $12M | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Protein analysis firm Cell Biosciences today said it has entered into a definitive agreement to buy Convergent Bioscience for $12 million in a cash deal.

The deal is expected to expand Cell Biosciences' protein analysis product portfolio "and transform Cell Biosciences into the premier provider of capillary-based protein analysis technology," the Santa Clara, Calif.-based company said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.